Aethlon Medical Amends Agreements, Allowing Immediate Exercisability of Pre-Funded Warrants

summarizeSummary

Aethlon Medical amended its financing agreements, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable and accelerating potential dilution.

check_boxKey Events

• Amendment to Securities Purchase Agreement

  On January 22, 2026, Aethlon Medical and an institutional investor amended their Securities Purchase Agreement from December 5, 2025.

• Amendment to Pre-Funded Common Stock Purchase Warrant

  Concurrently, the company and the investor also amended the Pre-Funded Common Stock Purchase Warrant from December 8, 2025.

• Removal of Shareholder Approval Requirement

  Both amendments removed the condition requiring shareholder approval under Nasdaq 5635 for the pre-funded warrants to become exercisable.

• Immediate Exercisability of Warrants

  As a direct result of these amendments, the pre-funded warrants are now immediately exercisable, accelerating potential dilution for existing shareholders.

auto_awesomeAnalysis

Aethlon Medical has amended its Securities Purchase Agreement and Pre-Funded Common Stock Purchase Warrant, removing the requirement for shareholder approval (under Nasdaq 5635) for the pre-funded warrants to become exercisable. This change, effective January 22, 2026, means these warrants are now immediately exercisable, accelerating potential dilution. This follows recent filings, including a DEF 14A on January 16, 2026, which sought shareholder approval for proposals enabling over 200% dilution, and an S-1 registration on January 7, 2026, for the resale of over 2 million shares underlying various warrants. The removal of this shareholder safeguard for pre-funded warrants is a significant negative development, as it allows for immediate dilution without prior shareholder consent, intensifying the dilution risk for existing investors.